2 results about "PCA3" patented technology

This invention belongs to the field of biodetection technology and discloses a fluorescence detection method for the prostate cancer biomarker PCA3 based on gold nanorods and CRISPR Cas12a amplification. This invention provides a detection kit for the ultrasensitive detection of the long non-coding RNA PCA3, a tumor marker for prostate cancer. This kit utilizes the paracleavage property of CRISPR Cas12a activated by the target sequence to cleave the fluorescent reporter probe, releasing the fluorophore. This removes the signal quenching effect of the gold nanorods on the fluorophore, restoring the fluorescence signal and achieving ultrasensitive detection of the target sequence. The limit of detection (LOD) of this kit is as low as 1.65 pM, achieving highly selective quantitative detection of PCA3.

The invention provides a prostate cancer detection kit, a detection system, a detection method and application, the kit simultaneously detects Ct values of PCA3 and PSA in a urine sample, namely CtPCA3 and CtPSA; the kit comprises a first specific amplification primer and a probe group aiming at a PCA3 gene, and a second specific amplification primer and a probe group aiming at a PSA gene, the kit interprets the detection result according to the delta Ct value, and delta Ct = CtPCA3-CtPSA. The detection kit and the detection system have the advantages of simple operation process, short time consumption, simple result interpretation method, good result repeatability and specificity, and high coincidence rate with clinical evaluation indexes.